Sugi Predict

Sugi Predict / Compounds / SCHEMBL197699

SCHEMBL197699

SCHEMBL197699

COC(=O)CCc1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B1 P15538 1/20 0.58
▸ CYP11B2 P19099 1/20 0.58
▸ PLAAT3 P53816 1/20 0.56
▸ PLAAT5 Q96KN8 1/20 0.56
▸ PLAAT2 Q9NWW9 1/20 0.56
▸ PLAAT4 Q9UL19 1/20 0.56
▸ KMT2A Q03164 3/20 0.51
▸ ATM Q13315 1/20 0.51
▸ HDAC1 Q13547 2/20 0.50
▸ HDAC6 Q9UBN7 2/20 0.50
▸ HDAC3 O15379 1/20 0.50
▸ HDAC4 P56524 1/20 0.50
▸ HDAC7 Q8WUI4 1/20 0.50
▸ HDAC2 Q92769 1/20 0.50
▸ HDAC10 Q969S8 1/20 0.50
▸ HDAC11 Q96DB2 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50
▸ HDAC9 Q9UKV0 1/20 0.50
▸ HDAC5 Q9UQL6 1/20 0.50
▸ CYP4F2 P78329 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4982350 0.90 CYP11B1 (0.51) CYP11B1CYP11B2PLAAT3PLAAT5PLAAT2
SCHEMBL22922181 0.90 CYP4F2 (0.59) KMT2ACYP4F2CYP4A11ALDH1A1POLB
SCHEMBL7155267 0.89 HDAC3 (0.56) CYP11B1CYP11B2PLAAT3PLAAT5PLAAT2
SCHEMBL11252363 0.87 FFAR1 (0.71) CYP11B1CYP11B2KMT2AHDAC1FFAR1
SCHEMBL5567796 0.85 ADRB2 (0.51) CYP11B1CYP11B2KMT2ACYP4F2CYP4A11
Cyclopropane SCHEMBL11851783 0.83 HDAC3 (0.58) CYP11B1CYP11B2PLAAT3PLAAT5PLAAT2
SCHEMBL3367245 0.83 IDO1 (0.59) KMT2AHDAC1HDAC6HDAC3HDAC4
SCHEMBL2569441 0.82 L3MBTL1 (0.55) PLAAT3PLAAT5PLAAT2PLAAT4KMT2A
SCHEMBL3679325 0.82 CYP4A11 (0.72) KMT2ACYP4F2CYP4A11ALDH1A1F2RL1
SCHEMBL1410420 0.82 CYP4A11 (0.56) KMT2ACYP4F2CYP4A11ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
CN-116640104-B Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2024-04-02 — — CN claimed
CN-116640104-A Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2023-08-25 — — CN claimed
CN-116283699-A Method for synthesizing fluoroalkyl substituted pyrrolidine 遵义医科大学 2023-06-23 — — CN claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 — — US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 — — EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 — — WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 — — US claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN disclosed
CN-116640104-B Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2024-04-02 — — CN disclosed
CN-116640104-B Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2024-04-02 — — CN disclosed
CN-116640104-A Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2023-08-25 — — CN disclosed
CN-116640104-A Industrial synthesis method of telithromycin 杭州科耀医药科技有限公司 2023-08-25 — — CN disclosed
CN-112876482-B Polysubstituted heterocyclic derivative, preparation method and medical application thereof 中国药科大学 2023-07-28 — — CN disclosed
US-6660756-B2 N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-12-09 — — US disclosed
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PFIZER INC. 2003-06-05 — — US disclosed
US-4797417-A ALDOSE REDUCTASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-01-10 — — US disclosed
US-4026709-A Color photographic recording material CIBA-GEIGY AG (CH) 1977-05-31 — — US disclosed
US-3984432-A PHOSPHONIC ACID AND PHOSPHORIC ACID DERIVATIVES CIBA-GEIGY AG (CH) 1976-10-05 — — US disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105132-A1 N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase PREP, ENGASE, ENPEP CYP11B1 1100/4885CYP11B2 708/4885PLAAT3 1434/4885
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 CYP11B1 87/4885CYP11B2 72/4885PLAAT3 4233/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 CYP11B1 155/4885CYP11B2 113/4885PLAAT3 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.